Tomas Lindahl and Karen Vousden become Fellows of the AACR Academy

17 March 2017

Tomas Lindahl and Karen Vousden

Image: Tomas Lindahl and Karen Vousden

Tomas Lindahl, Nobel prize-winner and emeritus scientists at the Francis Crick Institute, and Karen Vousden, Cancer Research UK's chief scientist and Group Leader at the Francis Crick Institute, have both been named as Fellows of the American Association for Cancer Research (AACR) Academy.

Tomas has been recognised for 'advancing the understanding of DNA damage repair through his discovery of the process of base excision repair and for isolating and characterizing several key components of the DNA repair machinery'.

Karen has been recognised for 'describing various p53 regulatory mechanisms involved in carcinogenesis, including MDM2 inhibition of p53 function and the role of p53 upregulated modulator of apoptosis (PUMA) in p53-mediated cell death'.

Commenting on his recognition, Tomas said: "I was, of course, pleased and honoured by this recognition of my work on DNA repair and endogenous DNA damage. I am particularly pleased to share this recognition by AACR with Karen Vousden, who has done such exciting novel research on the role of p53 in growth regulation, as well as creating a superb cancer research unit at the Beatson Institute in Glasgow, before taking on a UK wide role."

The AACR Academy serves to recognize and honour distinguished scientists whose major scientific contributions have propelled significant innovation and progress against cancer. Only individuals whose work has had a significant and enduring impact on the field are eligible for election as AACR Fellows.

The AACR Academy Fellows comprise a 'brain trust' of global leaders in cancer research who, when needed, provide scientific insight and expert guidance in science policy to the AACR, as the organisation pursues its mission to accelerate the prevention and cure of all cancers.

"This year's newly elected Fellows from the US and around the world have made quintessential scientific discoveries that have and continue to revolutionize how we study, treat, and prevent cancer. We are thrilled to announce their election and induction into the AACR Academy," said Margaret Foti, chief executive officer of the AACR.